To search for optimal immunization conditions for inducing protective immunity against
upper genital tract pathologies caused by chlamydial intravaginal infection, we compared …

Chlamydia trachomatis is the most common bacterial sexually transmitted disease in the
world and specifically in the United States, with the highest incidence in age-groups 14–19 …

IL-17 is believed to be important for protection against extracellular pathogens, where
clearance is dependent on neutrophil recruitment and local activation of epithelial cell …

Chlamydia trachomatis infections in women are often asymptomatic and if left untreated can
lead to significant late sequelae including pelvic inflammatory disease and tubal factor …

There is currently no licensed vaccine against Chlamydia trachomatis, the leading cause of
sexually transmitted bacterial disease worldwide. Conventional vaccination attempts using …

Background The chlamydial proteins CT443 (OmcB) and CT521 (rl16) have previously been
identified as human B and/or T cell targets during a chlamydial infection in humans. Here we …

Chlamydia trachomatis is a major cause of sexually transmitted disease (STD) for which a
vaccine is needed. CD4+ T-helper type 1 (Th1) cell-mediated immunity is an important …

A vaccine against genital tract infections caused by Chlamydia trachomatis is urgently
needed. We have previously identified a number of immunodominant human T-and/or B-cell …

An important consideration for antichlamydial vaccine development is the induction of cross-
serovar protection, since multiple serovars (D to L) of Chlamydia trachomatis cause genital …

To search for subunit vaccine candidates, immunogenic chlamydial antigens identified in
humans were evaluated for protection against both infection and pathology in a mouse …